Trial reportBJOG : an international journal of obstetrics and gynaecology2010
A combination of misoprostol and estradiol for preoperative cervical ripening in postmenopausal women: a randomised controlled trial.
Trial report in BJOG : an international journal of obstetrics and gynaecology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Preoperative ripening of the cervix before operative hysteroscopy.The Cochrane database of systematic reviews · 2015Pooled it
- Clinical practice in office hysteroscopy.Obstetrics & gynecology science · 2025Article
- Effect of misoprostol on type 3 transformation zone of the cervix among Cameroonian women.Gynecologic oncology reports · 2022Article
- Misoprostol and estradiol to enhance visualization of the transformation zone during cervical cancer screening: An integrative review.European journal of obstetrics, gynecology, and reproductive biology · 2022Review
- Surgical Assessment of Tissue Quality during Pelvic Organ Prolapse Repair in Postmenopausal Women Pre-Treated Either with Locally Applied Estrogen or Placebo: Results of a Double-Masked, Placebo-Controlled, Multicenter Trial.Journal of clinical medicine · 2021Article
- Local oestrogen therapy modulates extracellular matrix and immune response in the vaginal tissue of post-menopausal women with severe pelvic organ prolapse.Journal of cellular and molecular medicine · 2019Article
- Role of vaginal estradiol pretreatment combined with vaginal misoprostol for cervical ripening before operative hysteroscopy in postmenopausal women.Obstetrics & gynecology science · 2016Article
- Effect of misoprostol for cervical priming before gynecological procedures on nonpregnant premenopausal women.Journal of natural science, biology, and medicine · 2015Article
- Intracervical versus vaginal misoprostol for cervical dilatation prior to operative hysteroscopy-a comparative study.Medical journal, Armed Forces India · 2012Article
- Snippets.Reviews in obstetrics & gynecology · 2010Article
- The use of misoprostol for cervical priming prior to hysteroscopy: a systematic review and analysis.Drug design, development and therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the impact of 1000 microg of self-administered vaginal misoprostol versus self-administered vaginal placebo on preoperative cervical ripening after 2 weeks of pretreatment with estradiol vaginal tablets in postmenopausal women prior to day-care operative hysteroscopy.
designRandomised, double-blind, placebo-controlled sequential trial.
settingNorwegian university teaching hospital. POPULATION: Sixty-seven postmenopausal women referred for day-care operative hysteroscopy.
methodsThe women were randomised to receive either 1000 microg of self-administered vaginal misoprostol or self-administered vaginal placebo on the evening before day-care operative hysteroscopy. All women had administered a 25-microg vaginal estradiol tablet daily for 14 days prior to the operation.
main outcome measuresPRIMARY OUTCOME: preoperative cervical dilatation at hysteroscopy. SECONDARY OUTCOMES: difference in dilatation at recruitment and before hysteroscopy, number of women who achieved a preoperative cervical dilatation of 5 mm or more, acceptability, complications and adverse effects.
resultsThe mean cervical dilatation was 5.7 mm (SD, 1.6 mm) in the misoprostol group and 4.7 mm (SD, 1.5 mm) in the placebo group, the mean difference in cervical dilatation being 1.0 mm (95% CI, 0.2-1.7 mm). Self-administered vaginal misoprostol of 1000 microg at home on the evening before day-care hysteroscopy is safe and highly acceptable, although a small proportion of women experienced lower abdominal pain.
conclusionsOne thousand micrograms of self-administered vaginal misoprostol, 12 hours prior to day-care hysteroscopy, after 14 days of pretreatment with vaginal estradiol, has a significant cervical ripening effect compared with placebo in postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.